ciprofloxacin DPI

October 24, 2019October 24, 2019

Inhaled Ciprofloxacin May Help Prevent Bronchiectasis Exacerbation, but More Studies are Needed, Review Suggests

News

Treatment with inhaled ciprofloxacin medications — such as Aradigm’s Apulmiq or Bayer’s Ciprofloxacin DPI investigational therapies — holds potential to prevent acute worsening of respiratory problems in patients with bronchiectasis, ... Read more

January 4, 2018January 4, 2018

Bayer’s Ciprofloxacin DPI Shows Promise in Treating Non-cystic Fibrosis Bronchiectasis

News

Bayer is conducting two Phase 3 clinical trials evaluating ciprofloxacin Dry Powder for Inhalation (ciprofloxacin DPI) as a treatment for non-cystic fibrosis (non-CF) bronchiectasis, and preliminary data show promising results. The ... Read more

October 19, 2016October 19, 2016

#CHEST2016 – Bayer to Present Data from Phase 3 Trial on Non-CF Bronchiectasis Therapy

News

Bayer will present data from current trials in non-cystic fibrosis (non-CF) bronchiectasis and pulmonary arterial hypertension at the American College of Chest Physicians (CHEST 2016) Oct. 22-26 in Los Angeles. “Our data reflects Bayer’s ... Read more